Mineralys Therapeutics (MLYS) announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension will be presented in a late-breaking clinical trials session at the American College of Cardiology’s Annual Scientific Session & Expo, which is being held in Chicago on March 29-31, 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today
- Mineralys Therapeutics 12.96M share Secondary priced at $13.50
- Mineralys Therapeutics announces $250M common stock offering
- Buy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study Outcomes